Sacituzumab govitecan is an SN-38 ADC targeting trophoblast cell-surface antigen 2 (TROP-2), which received a breakthrough therapy designation from the FDA in 2021 for the treatment of relapsed patients with metastatic triple-negative breast cancer [67]. The gene discussed is TACSTD2; the disease is triple-negative breast carcinoma.